Skyrizi ® (risankizumab-rzaa) is now available as a single-dose 150mg prefilled pen or syringe for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic ...

Previously two 75 mg injections per dose, SKYRIZI 150 mg is now administered with one injection per dose – via either a prefilled pen or syringe – every 12 weeks following two starter doses.

You’ll then likely receive a 150-mg dose of Skyrizi once every ... more information on how to self-inject Skyrizi using the prefilled pen, prefilled syringe, or on-body injector.

Skyrizi comes in two forms. The most common form is a prefilled device that is ready to be injected under the skin, so you do not need to learn how to use a syringe and needle. The medicine also ...

Skyrizi is supplied in a 150 mg/mL single dose pen, 150 mg/mL single-dose prefilled syringe, and 75 mg/0.83 mL single-dose prefilled syringe. The FDA has approved oral Rinvoq ® (upadacitinib ...

Use SKYRIZI exactly as your healthcare provider tells you to use it. SKYRIZI is available in a 150 mg/mL prefilled syringe and pen, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 ...

Use SKYRIZI exactly as your healthcare provider tells you to use it. SKYRIZI is available in a 150 mg/mL prefilled syringe and pen. This is not a complete summary of all safety information.